Innovations in the Diagnosis and Management of Uveitis: Promising Research to Address Unmet Patient Needs

Overview

Journal Ann Eye Sci

Publisher AME Publishing Company

Date 2022 Sep 1

PMID 36046549

Authors

Steven Yeh

Ye Huang

Joanne Thomas

Affiliations

Soon will be listed here.

Citing Articles

Intravitreal Administration of Avacincaptad Pegol in a Nonhuman Primate Model of Dry Age-Related Macular Degeneration.

Fujii R, Matsushita M, Itani Y, Hama A, Natsume T, Takamatsu H Pharmacol Res Perspect. 2024; 13(1):e70052.

PMID: 39722646 PMC: 11669843. DOI: 10.1002/prp2.70052.

References

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

Takayama K, Obata H, Takeuchi M . Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy. Ocul Immunol Inflamm. 2019; 28(3):509-512. DOI: 10.1080/09273948.2019.1603312. View

Welsh S, Corrie P . Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015; 7(2):122-36. PMC: 4346212. DOI: 10.1177/1758834014566428. View

Moorthy R, Moorthy M, Cunningham Jr E . Drug-induced uveitis. Curr Opin Ophthalmol. 2018; 29(6):588-603. DOI: 10.1097/ICU.0000000000000530. View

Urzua C, Velasquez V, Sabat P, Berger O, Ramirez S, Goecke A . Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2015; 93(6):e475-80. DOI: 10.1111/aos.12648. View

Miserocchi E, Giuffre C, Cornalba M, Pontikaki I, Cimaz R . JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020; 39(3):847-851. DOI: 10.1007/s10067-019-04875-w. View

Niccoli L, Nannini C, Cassara E, Gini G, Lenzetti I, Cantini F . Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2009; 93(11):1553-4. DOI: 10.1136/bjo.2008.153981. View

Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K . Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol. 1996; 8(5):799-803. DOI: 10.1093/intimm/8.5.799. View

Cunningham Jr E . Uveitis in children. Ocul Immunol Inflamm. 2001; 8(4):251-61. DOI: 10.1076/ocii.8.4.251.6459. View

10.

Paredes I, Ahmed M, Foster C . Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006; 14(2):87-90. DOI: 10.1080/09273940500536766. View

11.

Khalifa Y, Bailony M, Acharya N . Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocul Immunol Inflamm. 2010; 18(3):218-22. DOI: 10.3109/09273941003739910. View

12.

Dalvin L, Shields C, Orloff M, Sato T, Shields J . CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018; 38(6):1063-1078. DOI: 10.1097/IAE.0000000000002181. View

13.

Thomas J, Kuthyar S, Shantha J, Angeles-Han S, Yeh S . Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis. Ann Eye Sci. 2021; 6. PMC: 8202723. DOI: 10.21037/aes-2019-dmu-10. View

14.

Aggarwal K, Agarwal A, Deokar A, Mahajan S, Singh R, Bansal R . Distinguishing features of acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy on optical coherence tomography angiography and en face optical coherence tomography imaging. J Ophthalmic Inflamm Infect. 2017; 7(1):3. PMC: 5236035. DOI: 10.1186/s12348-016-0122-z. View

15.

Su E, Oza V, Latkany P . A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab. J Formos Med Assoc. 2019; 118(5):945-950. DOI: 10.1016/j.jfma.2018.12.014. View

16.

Couto C, Schlaen A, Frick M, Khoury M, Lopez M, Hurtado E . Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease. Ocul Immunol Inflamm. 2016; 26(3):485-489. DOI: 10.1080/09273948.2016.1236969. View

17.

Liu X, Peng X, Wang S, You Q, Li Y, Xiao Y . FEATURES OF OPTICAL COHERENCE TOMOGRAPHY FOR THE DIAGNOSIS OF VOGT-KOYANAGI-HARADA DISEASE. Retina. 2016; 36(11):2116-2123. DOI: 10.1097/IAE.0000000000001076. View

18.

Jeroudi A, Angeles-Han S, Yeh S . Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014; 45(4):332-4. PMC: 4575287. DOI: 10.3928/23258160-20140709-09. View

19.

Wang Y, Gaudio P . Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008; 16(4):167-71. DOI: 10.1080/09273940802204527. View

20.

da Silva F, Sakata V, Nakashima A, Hirata C, Olivalves E, Takahashi W . Enhanced depth imaging optical coherence tomography in long-standing Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2012; 97(1):70-4. DOI: 10.1136/bjophthalmol-2012-302089. View